Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-recombinant gC1qR antibody
- Development stage
- Preclinical
- Lead developer
- Stony Brook University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-recombinant gC1qR antibody refers to monoclonal or polyclonal antibodies generated against the purified recombinant form of the gC1qR protein (also known as C1qBP, HABP1, or p32). In the context of oncology research, particularly for acute myeloid leukemia (AML), these antibodies are designed to target gC1qR, which is overexpressed on the surface of malignant cells. gC1qR serves as a proliferative molecular signal and provides a platform for the generation of angiogenic and metastatic factors. Research presented at AACR 2018 compared these antibodies to those generated against whole U937 cells, noting that while anti-recombinant antibodies can decrease cell viability, antibodies raised against the native endogenous protein on mammalian cells may offer superior targeting and potency.
- Other names
- anti-purified recombinant gC1qR antibodyanti-gC1qR antibodyanti-gC-1qR antibodyanti-gC 1qR antibody
02
Targets
C1QBP (Globular C1q receptor)
Beyond the preview
Go deeper on anti-recombinant gC1qR antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-recombinant gC1qR antibody.